413 related articles for article (PubMed ID: 12397889)
1. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
[TBL] [Abstract][Full Text] [Related]
2. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
[TBL] [Abstract][Full Text] [Related]
3. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population.
Hannesdóttir K; Snaedal J
Nord J Psychiatry; 2002; 56(3):201-6. PubMed ID: 12079572
[TBL] [Abstract][Full Text] [Related]
4. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
[TBL] [Abstract][Full Text] [Related]
5. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
6. The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls.
Graham DP; Cully JA; Snow AL; Massman P; Doody R
Alzheimer Dis Assoc Disord; 2004; 18(4):236-40. PubMed ID: 15592137
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychometric tests in cross sectional and longitudinal studies - a regression analysis of ADAS - cog, SKT and MMSE.
Ihl R; Grass-Kapanke B; Jänner M; Weyer G
Pharmacopsychiatry; 1999 Nov; 32(6):248-54. PubMed ID: 10599935
[TBL] [Abstract][Full Text] [Related]
8. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
9. A total score for the CERAD neuropsychological battery.
Chandler MJ; Lacritz LH; Hynan LS; Barnard HD; Allen G; Deschner M; Weiner MF; Cullum CM
Neurology; 2005 Jul; 65(1):102-6. PubMed ID: 16009893
[TBL] [Abstract][Full Text] [Related]
10. Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID).
Verhey FR; Houx P; Van Lang N; Huppert F; Stoppe G; Saerens J; Böhm P; De Vreese L; Nordlund A; DeDeyn PP; Neri M; Peña-Casanova J; Wallin A; Bollen E; Middelkoop H; Nargeot MC; Puel M; Fleischmann UM; Jolles J
Int J Geriatr Psychiatry; 2004 Jan; 19(1):41-50. PubMed ID: 14716698
[TBL] [Abstract][Full Text] [Related]
11. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
12. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
[TBL] [Abstract][Full Text] [Related]
14. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Wiig EH; Annas P; Basun H; Andreasen N; Lannfelt L; Zetterberg H; Blennow K; Minthon L
Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
[TBL] [Abstract][Full Text] [Related]
15. Memory, language, and praxis in Alzheimer's disease: norms for outpatient clinical trial populations.
Doraiswamy PM; Bieber F; Kaiser L; Connors K; Krishnan KR; Reuning-Scherer J; Gulanski B
Psychopharmacol Bull; 1997; 33(1):123-8. PubMed ID: 9133763
[TBL] [Abstract][Full Text] [Related]
16. The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer disease assessment scale-cognitive subscale.
Pyo G; Elble RJ; Ala T; Markwell SJ
Alzheimer Dis Assoc Disord; 2006; 20(1):16-22. PubMed ID: 16493231
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study.
Ylikoski R; Jokinen H; Andersen P; Salonen O; Madureira S; Ferro J; Barkhof F; van der Flier W; Schmidt R; Fazekas F; Scheltens P; Waldemar G; Salvadori E; Pantoni L; Inzitari D; Erkinjuntti T;
Dement Geriatr Cogn Disord; 2007; 24(2):73-81. PubMed ID: 17565216
[TBL] [Abstract][Full Text] [Related]
18. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
[TBL] [Abstract][Full Text] [Related]
19. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
20. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Wesnes K; Edgar C; Andreasen N; Annas P; Basun H; Lannfelt L; Zetterberg H; Blennow K; Minthon L
Acta Neurol Scand; 2010 Oct; 122(4):270-7. PubMed ID: 20047570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
